> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Friendly Accelerated Approval Disclosures Improve Drug Understanding: Study
- URL: https://www.fdaweb.com/friendly-accelerated-approval-disclosures-improve-drug-understanding-study/
- Published: 2026-07-17T12:00:00.000Z
- Updated: 2026-09-14T13:43:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5161477

A [new study](https://link.springer.com/article/10.1007/s43441-026-01018-7?ref=fdaweb.com) suggests that direct-to-consumer prescription drug Web sites may better communicate the limitations of FDA accelerated approvals when disclosures use consumer-friendly language rather than technical wording drawn from physician labeling. The study, published 7/15 in *Therapeutic Innovation & Regulatory Science*, examined whether the presence, prominence, and wording of accelerated approval disclosures affected consumer understanding of the regulatory pathway.

Researchers conducted two studies involving 822 U.S. adults and 615 cancer patients and caregivers. Participants were randomly assigned to review one of five versions of a Web site for a fictional leukemia drug, including versions with different accelerated approval disclosures and a control version without a disclosure.

FDA’s accelerated approval pathway allows approval of drugs based on surrogate endpoints or other measures that are expected to predict clinical benefit, with companies required to conduct confirmatory trials to verify effectiveness. The study found that disclosures written in consumer-friendly language improved understanding of key accelerated approval concepts compared with disclosures based on physician labeling.

For example, participants who viewed consumer-friendly disclosures were more likely to understand that the drug had not been shown to help patients live longer. In one study, comprehension increased from 13.4% among those viewing physician-labeling language to 31.4% among those viewing consumer-friendly wording. Similar results were observed among cancer patients and caregivers.

Researchers found that simply including a disclosure increased awareness that accelerated approval information was available, but only consumer-friendly wording improved understanding of the uncertainty surrounding clinical benefit. Increasing the visual prominence of disclosures, however, produced limited effects on comprehension, they said.